Date: 3.12.2010
Researchers at Tufts University School of Engineering have reported the first successful production of the antibiotic erythromycin A, and two variations, using E. coli as the production host.
The work, published in the November 24, 2010, issue of Chemistry and Biology, offers a more cost-effective way to make both erythromycin A and new drugs that will combat the growing incidence of antibiotic resistant pathogens. Equally important, the E. coli production platform offers numerous next-generation engineering opportunities for other natural products with complex biosynthetic pathways.
Erythromycin A is a potent weapon in the treatment of bacterial infections. The bacterium Saccharopolyspora erythraea, which is found in the soil, naturally produces several variants of erythromycin. Erythromycin A is the most common and most biologically active.
More information:
"Complete Biosynthesis of Erythromycin A and Designed Analogs Using E. coli as a Heterologous Host," Haoran Zhang, Yong Wang, Jiequn Wu, Karin Skalina, and Blaine A. Pfeifer, Chemistry and Biology, November 24, 2010, DOI 10.1016/j.chembiol.2010.09.013
Source:
http://www.physorg.com/news/2010-11-erythromycin-coli.html
Gate2Biotech - Biotechnology Portal - All Czech Biotechnology information in one place.
ISSN 1802-2685
This website is maintained by: CREOS CZ
© 2006 - 2024 South Bohemian Agency for Support to Innovative Enterprising (JAIP)
Interesting biotechnology content:
Environmetal biotechnology - Information about environmetal biotechnology at Wikipedia
Science - Daily Czech science news
Will this antibiotic work for you? A quick and easy method of testing antimicrobial susceptibility
Reprogrammed T cells make mice (and maybe us) age slower